{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:12:57Z","timestamp":1769598777603,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jid.2023.01.017","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T17:21:38Z","timestamp":1675272098000},"page":"1246-1256.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["IFN-\u03b3 Signaling Sensitizes Melanoma Cells to BH3 Mimetics"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7175-6866","authenticated-orcid":false,"given":"Zizhen","family":"Ming","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9576-5441","authenticated-orcid":false,"given":"Su Yin","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5676-1982","authenticated-orcid":false,"given":"Ashleigh","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9278-5663","authenticated-orcid":false,"given":"Bernadette","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6155-1020","authenticated-orcid":false,"given":"Elena","family":"Shklovskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5183-7562","authenticated-orcid":false,"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7861-4104","authenticated-orcid":false,"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9251-9229","authenticated-orcid":false,"given":"Richard F.","family":"Kefford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8844-3444","authenticated-orcid":false,"given":"Jenny H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8991-0013","authenticated-orcid":false,"given":"Richard A.","family":"Scolyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-3545","authenticated-orcid":false,"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2094-9198","authenticated-orcid":false,"given":"Helen","family":"Rizos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2023.01.017_bib1","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1093\/annonc\/mdy139","article-title":"T\u00a0cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression","volume":"29","author":"Andersen","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jid.2023.01.017_bib2","doi-asserted-by":"crossref","first-page":"9504","DOI":"10.1200\/JCO.2021.39.15_suppl.9504","article-title":"Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004","volume":"39","author":"Arance","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2023.01.017_bib3","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41591-019-0448-9","article-title":"Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma","volume":"25","author":"Ascierto","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2023.01.017_bib4","doi-asserted-by":"crossref","first-page":"6832","DOI":"10.1074\/jbc.M706021200","article-title":"Interferon-gamma induces X-linked inhibitor of apoptosis-associated factor-1 and Noxa expression and potentiates human vascular smooth muscle cell apoptosis by STAT3 activation","volume":"283","author":"Bai","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jid.2023.01.017_bib5","doi-asserted-by":"crossref","first-page":"39632","DOI":"10.1074\/jbc.M111.253591","article-title":"Cytokines tumor necrosis factor-\u03b1 and interferon-\u03b3 induce pancreatic \u03b2-cell apoptosis through STAT1-mediated Bim protein activation","volume":"286","author":"Barthson","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jid.2023.01.017_bib6","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jid.2023.01.017_bib7","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2023.01.017_bib8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","article-title":"Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function","volume":"17","author":"Chen","year":"2005","journal-title":"Mol Cell"},{"key":"10.1016\/j.jid.2023.01.017_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jid.2023.01.017_bib10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2023.01.017_bib11","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41591-020-1082-2","article-title":"Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i","volume":"26","author":"Dummer","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2023.01.017_bib13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jid.2023.01.017_bib14","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","article-title":"Conserved interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma","volume":"38","author":"Grasso","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jid.2023.01.017_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41408-022-00710-9","article-title":"Venetoclax ex\u00a0vivo functional profiling predicts improved progression-free survival","volume":"12","author":"Gupta","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jid.2023.01.017_bib16","doi-asserted-by":"crossref","first-page":"212574","DOI":"10.7573\/dic.212574","article-title":"Venetoclax: evidence to date and clinical potential","volume":"8","author":"Ju\u00e1rez-Salcedo","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.jid.2023.01.017_bib17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","article-title":"Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade","volume":"11","author":"Kohlhapp","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jid.2023.01.017_bib18","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jid.2023.01.017_bib19","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2023.01.017_bib20","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/s41467-020-15726-7","article-title":"Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition","volume":"11","author":"Lee","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2023.01.017_bib21","doi-asserted-by":"crossref","first-page":"101116","DOI":"10.1016\/j.tranon.2021.101116","article-title":"the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade","volume":"14","author":"Li","year":"2021","journal-title":"Transl Oncol"},{"key":"10.1016\/j.jid.2023.01.017_bib22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"10.1016\/j.jid.2023.01.017_bib23","doi-asserted-by":"crossref","first-page":"9503","DOI":"10.1200\/JCO.2021.39.15_suppl.9503","article-title":"Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: primary phase III results from RELATIVITY-047 (CA224-047)","volume":"39","author":"Lipson","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2023.01.017_bib24","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","article-title":"BH3-mimetic drugs: blazing the trail for new cancer medicines","volume":"34","author":"Merino","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jid.2023.01.017_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19010089","article-title":"The dark side of IFN-\u03b3: its role in promoting cancer immunoevasion","volume":"19","author":"Mojic","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2023.01.017_bib26","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1158\/2159-8290.CD-18-0277","article-title":"Exploiting MCL1 dependency with combination MEK\u00a0+ MCL1 inhibitors leads to induction of apoptosis and tumor regression in KRAS-mutant non-small cell lung cancer","volume":"8","author":"Nangia","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jid.2023.01.017_bib27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jid.2023.01.017_bib28","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nature02067","article-title":"Development and maintenance of B and T lymphocytes requires anti-apoptotic MCL-1","volume":"426","author":"Opferman","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jid.2023.01.017_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jid.2023.01.017_bib30","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jid.2023.01.017_bib31","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jid.2023.01.017_bib32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2023.01.017_bib33","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1038\/s41467-019-12409-w","article-title":"Targeting melanoma\u2019s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1\/2 pathway inhibitors","volume":"10","author":"Sale","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2023.01.017_bib48","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jid.2023.01.017_bib34","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jid.2023.01.017_bib35","doi-asserted-by":"crossref","first-page":"15440","DOI":"10.1038\/ncomms15440","article-title":"Acquired IFN\u03b3 resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions","volume":"8","author":"Sucker","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2023.01.017_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.nbd.2005.09.014","article-title":"Interferon-gamma induces microglial-activation-induced cell death: a hypothetical mechanism of relapse and remission in multiple sclerosis","volume":"22","author":"Takeuchi","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.jid.2023.01.017_bib37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jid.2023.01.017_bib38","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2023.01.017_bib39","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1002\/ijc.33000","article-title":"Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma","volume":"147","author":"Tseng","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jid.2023.01.017_bib40","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1101\/gad.1304105","article-title":"Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins","volume":"19","author":"Willis","year":"2005","journal-title":"Genes Dev"},{"key":"10.1016\/j.jid.2023.01.017_bib41","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2023.01.017_bib42","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/jcmm.12876","article-title":"LIGHT\/IFN-\u03b3 triggers \u03b2 cells apoptosis via NF-\u03baB\/Bcl2-dependent mitochondrial pathway","volume":"20","author":"Zheng","year":"2016","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.jid.2023.01.017_bib43","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jid.2023.01.017_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087293","article-title":"Evaluating strategies to normalise biological replicates of Western blot data","volume":"9","author":"Degasperi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2023.01.017_bib45","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1046\/j.0022-202X.2004.22237.x","article-title":"Interferon-\u03b3-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals","volume":"122","author":"Kortylewski","year":"2004","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2023.01.017_bib46","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/s41467-020-15726-7","article-title":"Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition","volume":"11","author":"Lee","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2023.01.017_bib47","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23000726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23000726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T01:18:43Z","timestamp":1719796723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X23000726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0022202X23000726"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2023.01.017","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IFN-\u03b3 Signaling Sensitizes Melanoma Cells to BH3 Mimetics","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2023.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}